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There is much evidence for a causal relationship between salt intake and blood pressure (BP). The current salt intake in many countries is
between 9 and 12 g/day. A reduction in salt intake to the recommended level of 5–6 g/day lowers BP in both hypertensive and normotensive
individuals. A further reduction to 3–4 g/day has a much greater effect. Prospective studies and outcome trials have demonstrated that a
lower salt intake is associated with a decreased risk of cardiovascular disease. Increasing evidence also suggests that a high salt intake is
directly related to left ventricular hypertrophy (LVH) independent of BP. Both raised BP and LVH are important risk factors for heart
failure. It is therefore possible that a lower salt intake could prevent the development of heart failure. In patients who already have heart
failure, a high salt intake aggravates the retention of salt and water, thereby exacerbating heart failure symptoms and progression of the
disease. A lower salt intake plays an important role in the management of heart failure. Despite this, currently there is no clear evidence
on how far salt intake should be reduced in heart failure. Our personal view is that these patients should reduce their salt intake to
,5 g/day, i.e. the maximum intake recommended by the World Health Organisation for all adults. If salt intake is successfully reduced,
there may well be a need for a reduction in diuretic dosage.
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For several million years, the ancestors of humans, like all other
mammals, ate a diet which contained a very small amount of salt
that existed in natural foods, i.e. ,0.5 g of salt (0.2 g sodium)
per day.1 Only 5 000 years ago, the Chinese discovered that
salt could be used to preserve foods. Salt then became of great
economic importance and the most taxed, traded commodity in
the world, with intake reaching a peak around the 1870s.1
However, with the invention of the deep freezer and the refriger-
ator, salt was no longer required as a preservative. Salt intake had
been declining, but with the recent large increase in the consump-
tion of highly salted processed foods, salt intake is now increasing
again. The current salt intake in many countries is between 9 and
12 g/day.2 This large increase in salt intake is relatively recent in
evolutionary terms. It presents a major challenge to the physiologi-
cal systems to excrete these large amounts of salt through the
kidneys. The consequence is a gradual rise in blood pressure
(BP),3,4 thereby increasing the risk of stroke, heart attack, heart
failure, and renal disease. Furthermore, a high salt intake may
have direct effects on stroke,5,6 left ventricular hypertrophy
(LVH),7 progression of renal disease and proteinuria,8 independent
of but additive to the effect of salt on BP. There is also evidence
that a high salt intake is indirectly related to obesity through
increased soft drink consumption,9,10 associated with a higher
risk of renal stones and osteoporosis,11 and probably a major
cause of stomach cancer.12,13 The evidence on these harmful
effects of salt has been comprehensively examined in several
recent review articles.3,14 In this paper, we focus on the evidence
relating salt to BP, LVH, heart failure, and total cardiovascular
disease.
Salt and blood pressure
Raised BP is a major cause of cardiovascular disease, responsible
for 62% of stroke and 49% of coronary heart disease.15 Impor-
tantly, the risk is not limited to those with hypertension (i.e. systo-
lic BP ≥140 or diastolic ≥90 mmHg), but throughout the range of
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BP, starting at 115/75 mmHg.16 It has been shown that a high salt
intake, a low consumption of fruit and vegetables (i.e. low potass-
ium intake), obesity, excess alcohol intake, and lack of physical
exercise all contribute to the development of high BP. However,
the diversity and strength of the evidence is much greater for
salt than for other factors. The evidence for salt comes from
studies in animals, human genetics, epidemiology, migration,
population-based intervention, and treatment trials.3 These
studies have consistently shown that dietary salt intake is a major
cause of raised BP.
Experimental studies in various species of animals, e.g. rat, dog,
chicken, rabbit, baboon, and chimpanzee, have shown that salt
intake plays an important role in regulating BP.17,18 A study in chim-
panzees (98.8% genetic homology with man) demonstrated that an
increase in salt intake from 0.5 g/day, which is close to humans’
evolutionary intake, to 10–15 g/day which is similar to our
current salt intake, caused progressive and large increases in
BP.17 A more recent study demonstrated that even a modest
reduction in salt intake had a significant effect on BP in chimpan-
zees. Additionally, the fall in BP was as large as or larger for salt
intakes at or below the recommended levels of 5–6 g/day.18
Genetic studies of rare Mendelian form of high or low BP have
shed light on the salt-BP relationship. About 20 different genes
have been identified.19 Most of these genes affect sodium handling
by the kidney and can have a dramatic effect on the BP of affected
individuals.19,20 Although such genetic disorders are very rare,
these studies clearly indicate the importance of salt intake in reg-
ulating BP in humans. Additionally, recent studies have suggested
a key role of salt consumption as an effect modifier in BP
genetics.21
Numerous epidemiological studies22– 26 have shown that non-
acculturated tribes who have a salt intake of ,3 g/day have a
lower BP, e.g. 96/61 mmHg for adult Yanomamo Indians, and
their BP does not rise with age.24 However, undeveloped tribes
who have access to salt, e.g. the Qash’qai in Iran, develop high
BP and a rise in BP with age similar to that which occurs in
Western communities, but they live a lifestyle similar to non-
acculturated societies.25 In spite of this evidence, it was felt necess-
ary to set up a large international study on salt and BP (INTER-
SALT)4 using standardized methods for measuring 24-h urinary
sodium and BP. The intention was to study communities with a
wide range of salt intake, e.g. from 0.5 to 25 g/day. A total of
10 079 individuals from 52 centres around the world were
recruited into the study. However, among these 52 communities,
only 4 had a low salt intake (i.e. ≤3 g/day) and the majority lay
between 6 and 12 g/day and none had the high salt intake as orig-
inally envisaged. Nevertheless, the study demonstrated a significant
positive relationship between salt intake and BP. There was also a
highly significant positive relationship between salt intake and the
increase in BP with age (Figure 1). It was estimated that an increase
of 6 g/day in salt intake over 30 years would lead to an increase in
systolic BP by 9 mmHg.4
One criticism of the INTERSALT study made by the Salt Insti-
tute (a public relations company defending the interests of salt
extractors and manufacturers worldwide) was that when the
four communities consuming lower salt were excluded, there
was no overall relationship remaining between salt intake and BP.
The INTERSALT’s investigators re-analysed their data and
showed that the highly significant within-population association
between salt intake and BP across all 52 centres was virtually
unchanged when the 4 low-salt populations were excluded, and
the association between salt intake and the rise in BP with age per-
sisted across 48 centres.4,27,28 Other epidemiological studies, e.g.
the international study of macro- and micro-nutrients and BP,29
and the Norfolk Cohort of the European Prospective Investigation
into Cancer,30 have lent further support for the important role of
salt intake in determining the levels of population BP.
Migration studies, e.g. the Luo migrants in Kenya and the Yi
migrants in China, have shown that migration from isolated
low-salt societies to an urban environment with a high salt intake
is associated with an increase in BP.31,32
Population-based intervention studies have shown that when
salt intake is decreased, there is a reduction in population
BP.33,34 One of the most successful intervention studies was con-
ducted in two similar villages in Portugal33 where salt intake was
very high (21 g/day) and the prevalence of hypertension and
stroke was also very high. During 2 years of intervention through
vigorous, widespread health education to reduce the consumption
of salt especially from foods that had previously been identified as
the major sources of salt, there was a difference of 50% in salt
intake between the two villages (i.e. intervention vs. control).
This was associated with a difference of 13/6 mmHg in BP
(Figure 2). Another community-based intervention trial in two
rural villages in north-eastern Japan reduced salt intake by 2.3 g/
day through dietary counselling for 1 year. This reduction in salt
Figure 1 Relationship between salt intake and the slope of the
rise in systolic blood pressure with age in 52 centres in the
INTERSALT study (adapted from Ref.4).
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intake was associated with a decrease of 3.1 mmHg in systolic BP.35
Several other studies,36,37 however, failed to achieve a reduction in
salt intake in the intervention group, it is therefore not surprising
that there was no change in BP in such studies.
There have been a large number of randomized trials looking at
the effect of a reduction in salt intake on BP in both hypertensive
and normotensive individuals. Several meta-analyses of these trials
have been performed.38– 42 In two meta-analyses,39,41 it was
claimed that salt reduction had very little effect on BP in individuals
with normal BP and a reduction in population salt intake was not war-
ranted. However, these two meta-analyses are flawed. Both included
trials of very short duration with many comparing the effects of acute
salt loading to abrupt and severe salt restriction, e.g. from 20 to
,1 g/day for only a few days. It is known that such acute changes
in salt intake increase sympathetic activity, plasma renin activity,
and angiotensin II,43 which would counteract the effects on BP. Fur-
thermore, most BP-lowering drugs do not exert their maximal
effects within a few days. This is particularly true with diuretics
which are likely to work by a similar mechanism to that of salt
reduction. It is therefore inappropriate to include the acute salt
restriction trials in a meta-analysis that attempts to apply them to
public health recommendations for a longer term modest reduction
in salt intake. A meta-analysis by Hooper et al.42 attempted to look at
whether salt reduction for ≥6 months caused a fall in BP. However,
most trials included in this meta-analysis achieved only a very small
reduction in salt intake. It is, therefore, not surprising that there
was only a small, but still significant fall in BP. A more recent
meta-analysis of randomized trials of 1 month or longer, demon-
strated that a modest reduction in salt intake caused significant and
important falls in BP in both hypertensive and normotensive individ-
uals.44 Furthermore, there was a dose–response to salt reduction. A
reduction of 6 g/day would lower BP by 7/4 mmHg in hypertensives
and 4/2 mmHg in normotensives (Figure 3).44
The best way to study the dose–response relationship between
salt intake and BP is to look at the BP responses to several levels of
salt intake. So far, there are only two well-controlled trials that
studied three levels of salt intakes.45,46 One is the randomized
double-blind cross-over trial in 20 individuals with untreated
essential hypertension, where salt intake was reduced from 11.2
to 6.4 and 2.9 g/day, each for 1 month.45 Blood pressure was
163/100 mmHg with a salt intake of 11.2 g/day, and reduced to
155/95 mmHg when salt intake was decreased to 6.4 g/day (i.e. a
decrease of 8/5 mmHg). Blood pressure fell further to 147/
91 mmHg when salt intake was reduced to 2.9 g/day (i.e. a
further fall of 8/4 mmHg). After the trial was completed, individuals
continued the low salt intake. Among these 20 participants, 19
were followed up for one further year and the BP sustained at
the lowest level (i.e. 145/90 mmHg) with the lowest salt intake
of 3.0 g/day.45 The other well-controlled trial that has looked at
the dose–response is the DASH (Dietary Approaches to Stop
Hypertension)-Sodium study which is a feeding trial with all
foods and drinks provided to all participants for the entire
study.46 A total of 412 individuals with normal or mildly raised
BP were randomized into two groups, i.e. the normal American
diet and the DASH diet which is rich in fruits, vegetables, and
low-fat dairy products. Within each group, participants were
given three levels of salt intake 8, 6, and 4 g/day in a randomized
cross-over design, each for 1 month. The results demonstrated a
clear dose–response to salt reduction both on the normal Amer-
ican diet and the DASH-diet (Figure 4).46 From these well-
controlled trials, it is clear that the current recommendations to
reduce salt from 9–12 to 5–6 g/day will have a major effect on
BP, but are not ideal. A further reduction to 3 g/day will have a
much greater effect. It is important to note that the current rec-
ommendations are based on the feasibility of reducing population
salt intake to 5–6 g/day,47 but not on the potential maximum
Figure 3 Relationship between the reduction in 24-h urinary
sodium and the change in systolic blood pressure in a meta-
analysis of modest salt reduction trials. The open circles
represent normotensives and the solid circles represent hyper-
tensives. The slope is weighted by the inverse of the variance
of the net change in blood pressure. The size of the circle is in
proportion to the weight of the trial.
Figure 2 Changes in blood pressure in two Portuguese villages
in an intervention study. With the intervention, there was a differ-
ence of 42% in salt intake between the two villages at 1 year and
47% at 2 year. This was associated with a significant difference in
blood pressure (adapted from Ref.33).
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beneficial effects of salt reduction. Therefore, these are viewed as
interim targets. Recently the UK government’s health advisory
agency, the National Institute for Health and Clinical Excellence
has recommended a reduction in the population’s salt consump-
tion to 3 g/day by 2025.48
It has been shown that, for a given reduction in salt intake, the
fall in BP was larger in individuals of African origin, in older
people and in those with raised BP compared with whites, young
people and individuals with normal BP, respectively.49 These differ-
ences in the fall in BP were, at least in part, due to the differences
in the responsiveness of the renin–angiotensin system.50,51 The
term ‘salt sensitivity’ has been commonly used to describe the vari-
ations of BP response to salt reduction. However, almost all of the
studies on ‘salt sensitivity’ have used a protocol of very large and
sudden changes in salt intake. As described previously, these
studies are irrelevant to the public health recommendations of
more modest reduction in salt intake for a prolonged period of
time. There is strong evidence that a modest reduction in salt
intake should be carried out universally in the entire population.
A reduction in population salt intake lowers population BP. Even
a small reduction in BP across the whole population would have
a large impact on reducing the appalling burden of cardiovascular
disease.52
A reduction in salt intake is additive to other dietary and lifestyle
changes for lowering BP.46,53 The DASH-Sodium trial demon-
strated that the combination of a low salt and the DASH diet
had a greater effect on BP than either intervention alone, though
the combined effects were not as great as the simple addition of
each separate intervention (Figure 4).46 The Trial of Non-
pharmacologic Interventions in the Elderly (TONE) demonstrated
that a combination of salt reduction and weight loss were more
successful than either intervention alone in maintaining satisfactory
BP control after withdrawal of antihypertensive medication in
older people who were obese and had hypertension.53 The Trial
of Hypertension Prevention (TOHP) II also showed that salt
restriction combined with weight reduction had a greater effect
on reducing the incidence of hypertension during the first 6
months of the study in overweight people with high-normal BP.
However, this effect did not sustain over the following 30
months due to the failure of maintaining lower salt and weight.54
A reduction in salt intake is also additive to antihypertensive
drug treatments, enhances BP control, and reduces the need for
drug therapy.53,55 Salt restriction is particularly effective in lowering
BP when the renin–angiotensin system is blocked by an angioten-
sin–converting–enzyme inhibitor or angiotensin receptor blocker
because the reactive increase in plasma renin activity and thereby
angiotensin II that occurs with salt reduction, offsets the falls in
BP.55 In this respect, black hypertensive patients are usually con-
sidered as poor responders to a blocker of the renin–angiotensin
system and better responders to a diuretic because of their low
baseline plasma renin activity. However, in a group of black hyper-
tensive individuals who were on a lower salt intake, i.e. 6 g/day, a
better BP response to an angiotensin-converting enzyme inhibitor
than to a diuretic was found in a randomized cross-over trial.56
These results suggest that a reduction in salt intake may restore
the BP response to drugs that block the renin–angiotensin
system even in black hypertensive population.56 The TONE
study demonstrated that, in elderly hypertensive individuals after
withdrawal of medication, a very modest reduction in salt intake
of only 2.4 g/day reduced the occurrence of high BP, resumption
of medication and cardiovascular events by 32% (P, 0.001)
during a follow-up period of 28 months.57
Salt and left ventricular
hypertrophy and left ventricular
dysfunction
Left ventricular hypertrophy is an important predictor of cardio-
vascular outcomes.58 Raised BP is a major risk factor for LVH
and long-term treatment of hypertension has been shown to
result in regression of existing LVH.59 A reduction in salt intake
lowers BP, and therefore could reduce the risk of LVH. Increasing
evidence also suggests that salt intake may have a direct effect on
LVH independent of BP.60,61 A review of nine cross-sectional
studies in which salt intake and LV mass were assessed, has
shown a close positive correlation between the two, with corre-
lation coefficients ranging from 0.22 to 0.61.7 The relationship
Figure 4 Changes in blood pressure and 24-h urinary sodium
excretion with the reduction in salt intake in all participants
(hypertensives: n ¼ 169; normotensives: n ¼ 243) on the
normal American diet (i.e. control diet) and on DASH diet
(redrawn from Ref.46).
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was independent of other confounding factors including BP.7 A
reduction in salt intake has been shown to decrease LV mass in
hypertensive individuals.62 –64 A study in 10 hypertensive men
showed that when salt intake was reduced from 6.2 to 1.7 g/day
for 6 weeks, there was a significant decrease in echocardiographi-
cally determined LV mass.62 Two other studies (one reduced salt
intake by 5 g/day for 1 year and the other reduced salt intake
by 2 g/day for 4 years) demonstrated that salt reduction in combi-
nation with other dietary and lifestyle changes had a significant
effect on reducing LV mass.63,64
Diastolic dysfunction, characterized by abnormalities of ventri-
cular filling, can be present in hypertensive individuals without
overt hypertrophy, and may represent an early marker of
end-organ damage. Up to 50% of individuals with hypertension
have evidence of diastolic dysfunction.65 Treatment trials have
demonstrated that lowering BP improves diastolic function even
in individuals with mild hypertension and irrespective of the type
of antihypertensive agent used.66 A reduction in salt intake
lowers BP and could therefore have a beneficial effect on diastolic
function. It is of interest that some cross-sectional studies have
shown that a higher salt intake as measured by 24 h urinary
sodium excretion was associated with impaired LV diastolic func-
tion in hypertensive individuals67 and in patients with type II dia-
betes.68 Clearly, further studies are needed, in particular, to
investigate whether a longer term modest reduction in salt
intake, as currently recommended, has a significant effect on
cardiac function.
The pathophysiological mechanisms for a link between salt and
LV function are not fully understood. Experimental studies in rats
demonstrated that an increase in salt intake for a few weeks not
only caused LVH, but also led to widespread interstitial fibrosis
in the left ventricle and intramyocardial arteries and arterioles.69
Tissue culture experiments showed that increasing bath sodium
concentration in an amount similar to the increase in plasma
sodium which was seen with an increase in salt intake, caused
marked cellular hypertrophy in both arterial smooth muscle and
cardiac myocytes.70 The hypertrophy was due to an increase in
the rate of protein synthesis and a decrease in the rate of
protein degradation.70
Salt and cardiovascular disease
A reduction in salt intake lowers BP and, as raised BP throughout
its range is a major cause of cardiovascular disease, salt reduction
would be predicted to reduce cardiovascular risk. Based on the fall
in BP from a meta-analysis of randomized salt reduction trials,44 it
was estimated that a reduction of 6 g/day in salt intake would
reduce stroke by 24% and coronary heart disease by 18%. This
would prevent 35 000 stroke and coronary heart disease
deaths a year in the UK71 and 2.5 million deaths worldwide.
Prospective cohort studies have shown that a higher salt intake
is related to an increased risk of cardiovascular disease. A recent
meta-analysis of 13 cohort studies with 177 025 participants for
a follow-up between 3.5 and 19 years, showed that an increase
of 5 g/day in salt intake was associated with a 23% increase in
the risk of stroke and a 14% increase in total cardiovascular
disease.72 After excluding one study which had serious
methodological problems,73 the pooled analysis showed that a
5 g/day increase in salt intake was associated with a 17% increase
in cardiovascular disease risk (Figure 5).72
Outcome trials have demonstrated that a reduction in salt intake
leads to a decrease in cardiovascular risk. A follow-up study of indi-
viduals who took part in two large randomized salt reduction trials,
Trial of Hypertension Prevention (TOHP) I and II, showed a signifi-
cant effect of salt reduction on cardiovascular disease.74 In the
original trials, over 3000 participants with an average baseline BP
of 127/85 mmHg were randomized to a reduced salt group (for
18 months in TOHP I and 36–48 months in TOHP II) or to a
control group. Compared with the control group, individuals in
the intervention group reduced their salt intake by 25–30%
Figure 5 Relative risk of stroke and total cardiovascular disease
(CVD) associated with a 5 g/day increase in salt intake in a
meta-analysis of cohort studies (adapted from Ref.72).
Figure 6 Cumulative incidence of cardiovascular disease
(CVD) by salt intervention group in the Trial of Hypertension
Prevention (TOHP) I and II, adjusted for age, sex, and clinic
(adapted from Ref.74).
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from an average of 10 g/day. This resulted in a fall in BP of 1.7/
0.9 mmHg at 18 months (TOHP I) and 1.2/0.7 mmHg at 36
months (TOHP II). After the original trials were completed, partici-
pants were not given further dietary advice. A follow-up study at
10–15 years post trial showed that individuals who were originally
allocated to the reduced-salt group had a 25% lower incidence of
cardiovascular events after adjusting for confounding factors
(Figure 6).74 Another outcome trial of over 2.5 years in elderly Tai-
wanese veterans (n ¼ 1981) showed that switching from the usual
salt (i.e. sodium chloride) to potassium-enriched salt (49% sodium
chloride, 49% potassium chloride, 2% other additives) with a sub-
sequent reduction of 17% in salt intake and an increase of 76% in
potassium intake, as measured by urinary sodium/creatinine and
potassium/creatinine ratio, caused a 40% decrease in cardiovascu-
lar mortality.75 These results were likely to be attributable to both
a reduction in salt and an increase in potassium intake.
Salt and heart failure
Raised BP is a major cause of heart failure with hypertension pre-
ceding the development of heart failure in 90% of patients.76
Blood pressure treatment trials of 2–5 years have demonstrated
that lowering BP could reduce heart failure by over 50%.76 Left
ventricular hypertrophy and LV dysfunction are also important
independent risk factors for heart failure. As described previously,
a high salt intake increases BP and the risk of LVH and LV dysfunc-
tion, thereby increasing the risk of heart failure (Figure 7). A pro-
spective cohort study in 10 352 men and women has shown that
a higher salt intake was associated with a higher risk of developing
heart failure over a follow-up period of 19 years. This association
was found in overweight individuals, but not in those with normal
weight.77 Similarly, the administration of drugs that promote
sodium and fluid retention, such as non-steroidal anti-inflammatory
drugs78 or thiazolidinediones,79 have been shown to increase the
risk of congestive heart failure significantly.
In a healthy person, the balance between salt intake and
excretion is crucial in the control of extracellular volume. When
salt intake is increased, there is retention of salt and thereby
water. This expands extracellular volume. The increase in extra-
cellular volume is a trigger for various compensatory mechanisms
to allow an increase in urinary sodium excretion but at the
expense of continued retention of salt and water. With an increase
of 5 g/day in salt intake, e.g. from 5 to 10 g/day, there is an increase
of 1.0–1.5 L in extracellular volume. This corresponds to a gain
of 1.0–1.5 kg in body weight.80 In patients with heart failure, there
is already retention of salt and water. A high salt intake aggravates
this, thereby exacerbating heart failure symptoms and progression
of the disease. Even in well-compensated heart failure, a sudden
increase in salt intake (e.g. eating a very salty meal) causes a
rapid increase in extracellular volume and may precipitate left ven-
tricular failure.
A lower salt intake is the primary dietary strategy for the man-
agement of heart failure. A study by Hummel et al.81 in 443 heart
failure patients with preserved systolic function showed that advice
for salt-restricted diet was associated with a lower rate of hospital
readmission and death 30-days after hospital discharge. On the
contrary, a recent randomized trial by Paterna et al.82 suggested
that a lower salt intake had detrimental renal and neurohormonal
effects with worse clinical outcome. In this trial, 232 compensated
heart failure patients were randomized to receive a normal salt
intake of 120 mmol/day (7.1 g) or a lower salt intake of
80 mmol/day (4.7 g), with all participants taking high-dose oral
furosemide (250–500 mg, twice a day) and restricting fluid intake
to 1000 mL/day. At the same time, all patients were on captopril
75–150 mg/day and 87% of the patients were on spironolactone
25 mg/day. The results showed that individuals who were on the
lower salt intake had a higher rate of hospital readmission due
to worsening of heart failure and mortality during a follow-up
period of 6 months. A further study by the same group of
researchers used a similar protocol on salt intakes, but the
normal and lower salt intake was combined with different doses
of furosemide (250 or 125 mg, twice a day) and different
amount of fluid intake (1000 or 2000 mL/day).83 A total of eight
groups of different combinations were studied and each group
involved around 50 patients with compensated heart failure. The
results indicated that a combination of normal salt intake with
high dose of diuretic and fluid intake restriction was a better
approach in terms of neurohormonal responses and clinical
outcome, when compared with other combinations including a
lower salt intake.
It is important to note that, in the above trials82,83 particularly
the first one,82 patients were on high-dose furosemide,
angiotensin-converting enzyme inhibitor and spironolactone, and
they were already on the verge of sodium and water depletion.
It is therefore not surprising that a lower salt intake is harmful
under such circumstances, particularly when no attempt was
made to lower the dose of furosemide or spironolactone. In the
second trial,83 the dose of furosemide was lower compared with
that in the first trial. However, furosemide at a dose of 125 or
250 mg, twice a day, when combined with angiotensin-converting
enzyme inhibitor and spironolactone, could still lead to sodium
and water depletion. A lower salt intake would aggravate this.
Additionally, in the second trial83 there were only 50 participants
in each group and the number of cases with outcome, especially
mortality, was very small. Therefore, the results from the above
trials need to be interpreted with caution.
Diuretics are commonly prescribed for patients with heart
failure and clinical signs or symptoms of fluid retention.
However, the use of diuretics is not without side effects, and
this is particularly true with high doses. If diuretics are suddenly
Figure 7 Salt intake and heart failure.
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withdrawn in patients with a normal salt intake, there is rebound
retention of salt and water.84 This is because the compensatory
mechanisms that are induced to maintain sodium balance in the
presence of the diuretic are still acting several days after the
effect of the diuretic has worn off. There are two ways to mitigate
this rebound retention of salt and water. One is to gradually
reduce the dose. The other and better way is to place the
patient on a low salt diet so that only a small amount of salt can
be retained when diuretic treatment is stopped.84 Nevertheless,
most patients with heart failure will need to continue with the
diuretic treatment, however, even in these patients, a lower dose
of diuretic may be sufficient if salt intake is reduced.
The question is how far salt intake should be reduced in patients
with heart failure? Disappointingly there is no clear evidence to
address this question. Although all authority bodies have rec-
ommended salt restriction in patients with heart failure, many of
the guidelines are either vague or set a level which is even
higher than those recommended for the general population, e.g.
2.0–2.4 g/day of sodium (‘restricted’) and 3.0–4.0 g/day (‘moderate
restriction’).85 These are equivalent to a salt intake of 5.0–6.0 and
7.5–10 g/day, respectively. Obviously these recommended levels
are too high. The European Society of Cardiology Guidelines86
state that ‘Sodium restriction is recommended in symptomatic heart
failure to prevent fluid retention. Although no specific guidelines exist,
excessive intake of salt should be avoided. Patients should be educated con-
cerning the salt content of common foods.’ This recommendation is
graded as ‘Class IIa’ which is defined as ‘Weight of evidence/opinion is
in favour of usefulness/efficacy.’ The level of evidence for this rec-
ommendation is classified as ‘C’, i.e. ‘Consensus of opinion of the
experts and/or small studies, retrospective studies, registries.’ Clearly
well-controlled trials are needed to study what level of salt intake
should be in heart failure. Our personal view is that salt intake
should be reduced to ,5 g/day, i.e. the maximum intake rec-
ommended by the World Health Organisation for all adults. If
patients are successful in reducing salt intake, there may well be a
need for a reduction in the dose of diuretics.
Salt reduction is a cost-effective
public health measure to reduce
cardiovascular disease
Several studies have shown that a reduction in salt intake is one of
the most cost-effective interventions to reduce cardiovascular
disease in the population.87– 93 For instance, a recent study in
the USA showed that even a very modest reduction in salt
intake of only 10% which could be easily achieved, as demon-
strated in the UK,94 would prevent hundreds of thousands of
strokes and heart attacks over the lifetimes of adults aged 40–85
years who are alive today, and could save .$32 billion in
medical expenses in the USA alone.93 A larger decrease in salt
intake would result in a larger health improvement and greater
cost savings.91 The UK salt reduction campaigns which started in
2003/2004 have been successful and the average salt intake, as
measured by 24 h urinary sodium, has fallen from 9.5 to 8.6 g/
day by May 2008.94 The campaigns, which cost just £15 million,
led to 6000 fewer cardiovascular deaths per year, saving the
UK economy £1.5 billion per annum.48,95
Asaria et al.89 estimated the effects and cost of strategies to
reduce salt intake and control tobacco use for 23 low- and
middle-income countries that account for 80% of chronic disease
burden in the developing world. They demonstrated that, over
10 years (from 2006 to 2015), a 15% reduction in mean population
salt intake could avert 8.5 million cardiovascular deaths and a 20%
reduction in smoking prevalence could avert 3.1 million cardiovas-
cular deaths. The modest reduction in salt intake could be achieved
by a voluntary reduction in the salt content of processed foods and
condiments by manufacturers combined with a sustained mass-
media campaign aimed to encourage dietary change within house-
holds and communities. The cost for implementing such salt
reduction programmes was estimated to be US$0.09 per person
per year. The cost for tobacco control, including both price and
non-price measures, was US$0.26 per person per year
(Figure 8).89 These figures clearly suggest that a reduction in salt
intake is more, or at the very least just, as cost-effective as
tobacco control in terms of reducing cardiovascular disease on
its own, the leading cause of death and disability worldwide.
Conclusions
The evidence for a causal relationship between chronic high salt
intake, high BP, and cardiovascular disease is very strong. The total-
ity of the evidence for salt is more robust than for any other
dietary variables considered to be important in the prevention of
cardiovascular disease. A reduction in salt from the current
intake of 9–12 g/day to the recommended level of ,5–6 g/day
Figure 8 Number of cardiovascular disease (CVD) deaths
averted and the financial costs associated with implementation
of salt reduction and tobacco control in 23 low- and middle-
income countries (adapted from Ref.89).
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will have major beneficial effects on health along with major cost
savings in all countries around the world.
Each country should adopt a coherent and workable strategy to
reduce salt intake. In most developed countries, 80% of salt is
hidden in foods, i.e. added by the food industry.96 It is therefore
vital to persuade the food industry to make a gradual and sustained
reduction in the amount of salt they add to foods. Several
countries, e.g. Finland and the UK, have successfully carried out
salt reduction programmes and salt intake has already fallen.94,97
Many other countries, e.g. Australia, Canada, and the USA, are
also stepping up their activities to reduce salt intake. In many devel-
oping countries, where most of the salt consumed comes from salt
either added during cooking or from sauces, public health cam-
paigns are needed to encourage consumers to use less salt. A
modest reduction in population salt intake worldwide would
result in a major improvement in public health—similar to the pro-
vision of clean water and drains in the late nineteenth century in
Europe.
Conflict of interest: none declared.
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